MARKET

KYMR

KYMR

Kymera Therapeutics, Inc.
NASDAQ
31.14
-1.03
-3.20%
After Hours: 29.25 -1.89 -6.07% 18:32 05/13 EDT
OPEN
32.30
PREV CLOSE
32.17
HIGH
32.38
LOW
30.46
VOLUME
443.97K
TURNOVER
--
52 WEEK HIGH
53.27
52 WEEK LOW
19.45
MARKET CAP
2.03B
P/E (TTM)
-10.0542
1D
5D
1M
3M
1Y
5Y
1D
Kymera Therapeutics Price Target Cut to $70.00/Share From $72.00 by UBS
Dow Jones · 10h ago
Kymera Therapeutics Is Maintained at Buy by UBS
Dow Jones · 10h ago
UBS Maintains Buy on Kymera Therapeutics, Lowers Price Target to $70
Benzinga · 10h ago
KYMERA THERAPEUTICS INC <KYMR.O>: UBS CUTS TARGET PRICE TO $70 FROM $72
Reuters · 14h ago
Kymera Therapeutics price target lowered to $70 from $72 at UBS
TipRanks · 15h ago
U.S. RESEARCH ROUNDUP-ACI Worldwide, Expand Energy, First Solar
Reuters · 18h ago
Kymera Therapeutics’ Innovative IRF5 Degrader KT-579 Fuels Buy Rating with Promising Growth in Immunology
TipRanks · 18h ago
The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts
Benzinga · 1d ago
More
About KYMR
More
Kymera Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company's targeted protein degradation (TPD) platform, which it refers to as Pegasus, allows it to discover highly selective small molecule protein degraders with activity against disease-causing proteins throughout the body. It utilized its Pegasus platform to design novel protein degraders focused in the areas of immunology-inflammation and oncology, and it continues to apply its platform’s capabilities to additional therapeutic areas. Its clinical stage programs are IRAK4, STAT3, and MDM2, which each address high impact targets within biologically proven pathways, providing the opportunity to treat a range of immuno-inflammatory diseases, hematologic malignancies, and/or solid tumors.
Recently
Symbol
Price
%Change

Webull offers Kymera Therapeutics Inc stock information, including NASDAQ: KYMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KYMR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading KYMR stock methods without spending real money on the virtual paper trading platform.